Latest:
Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis
Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Rylan DeStefano
Latest:
Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL
Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.
Alexander Chehrazi-Raffle, MD
Alexander Chehrazi-Raffle, MD, is an assistant professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Latest:
Dr Chehrazi-Raffle on the TiNivo-2 Study of Tivozanib With/Without Nivolumab in mRCC
Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.
Cesar Rodriguez, MD
Latest:
EHA 2025 Insights: Emerging Developments and Future Perspectives for the Multiple Myeloma Treatment Landscape
Panelists discuss how emerging combination therapies such as bispecific antibodies with chimeric antigen receptor (CAR) T cells show promising response rates in patients with heavily refractory disease, while highlighting the ongoing unmet need to improve treatment access and educate community practices on advanced therapies.
Xingming Zhang
Latest:
Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC
Xingming Zhang, MD, discusses the rationale for investigating the combination of sintilimab and axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma in a phase 2 trial.
Tarek Mouhieddine, MD
Tarek Mouhieddine, MD, is a medical oncologist at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School.
Latest:
Dr Mouhieddine on Future Directions With Ferritin and ALC as Biomarkers in Myeloma
Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.
Shiruyeh Schokrpur, MD, PHD
Latest:
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.
Wojciech Jurczak, MD, PhD
Latest:
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable safety profile in older, anthracycline-ineligible patients with previously untreated large B-cell lymphoma.
Stephen L. Chan, MD, The Chinese University of Hong Kong
Latest:
Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022
Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.